This project follows a fisrt research project with the DESCAR-T registry project initiated on the same topic in April 2022.
This project will use data from French patients, included in the DESCAR-T registry, and Spanish patients diagnosed with Non-Hodgkin B Lymphoma who received a treatment by CAR T-cells.
The objective of this study is to better understand the efficacy and safety of CAR-T to treat patients relapsing or refractory after a treatment by bispecific antibody. This project also aims to compare the efficacy and safety of CAR-T after bispecific antibody versus other treatments.
Data from Spanish patients will be shared by the VHIO to the LYSARC, who will perform the statistical analyses. No link can be made from the data used in this project with the identity of French or Spanish patients.
To patients included in the DESCAR-T registry or who received CAR T-cells in Spain
If you would like to oppose or get more information about the treatment of your data in this project, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“.